Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017
Data Analyses from Phase 2 (PUNCH CD) and Phase 2B (PUNCH CD2) Clinical Trials of RBX2660 Focus on Changes in Microbiome Diversity, Universal Donor Findings, and the Lack of Association with Patient Demographics on Treatment Success
Download this press release (161 KB).
ROSEVILLE, MN (May 04, 2017) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that data analyses from the Phase 2 (PUNCH CD) and Phase 2B (PUNCH CD2) clinical trials of RBX2660 will be the subject of a podium presentation and two poster sessions during Digestive Disease Week (DDW) 2017 being held May 6-9, 2017 in Chicago. RBX2660 is a broad-spectrum microbiota suspension that is designed to rehabilitate the human microbiome by delivering live microbes into a patient’s intestinal tract to treat disease.
Lee Jones, president and CEO of Rebiotix, stated, “We are enthusiastic about the additional insight gleaned from the PUNCH CD and PUNCH CD2 trials of RBX2660 being presented at DDW. Overall, this is a very exciting time for Rebiotix. Based on the results of the Phase 2 program for RBX2660, including our recently announced positive top line data from the open-label Phase 2 study, we look forward to progressing RBX2660 into Phase 3 clinical development, solidifying our position as the most clinically advanced microbiome company in the industry.”
The schedule of Rebiotix-focused presentations at DDW is as follows: